Member Info for EmeraldCarrots

So what would you get for your £18m?

GDR tech.

The Genedrive® CYP2C19, CE approved.

The Genedrive® MT-RNR1, CE approved.

Contracts for both with the NHS.

More contracts coming in regularly from the NHS.

FDA approval for both machines to come.

Etc.....

Mad.

This is why I have over 1m shares.

All IMHO.

So what would you get for your £18m?

GDR tech.

The Genedrive® CYP2C19, CE approved.

The Genedrive® MT-RNR1, CE approved.

Contracts for both with the NHS.

More contracts coming in regularly from the NHS.

FDA approval for both machines to come.

Etc.....

Mad.

All IMHO.

Bid coming in at 3p a share then?

Be £18m, and the offereor could rightly say they have offered a 100% preminum on the current price.

What can one say?

I just started the rumour with this.

LOL!

JimiHendrix.

So the person doing this implementation guide is what................ 3 months late. FFS!

WHAT A JOKE. Why are these people employed?

Angle still have a huge amount going for them.

The way the Company has been run is the problem.

- Millions of pounds wasted opening offices/labs in the USA, then closing them down when there was not enough demand for Parsortix.

Erm... are you not supposed to check demand before ploughing millions of pounds into offices/labs abroad?

Who's fault? The CEO, Mr Newland of course. What did the sp go to after the hype........ £1.70p I seem to remember.

The sp is 8p now. Hmmmm.............!!!!!!!

- The other major waste of money seems to be the sales team and that is on-going.

I mean, what have they achieved? Why has the management not shaken up the sales side????

Beggars’ belief.

What do they have going for them?

The Parsortix machine that can catch circulating tumour cells from a blood draw that are live and intact perfect for DNA analysis or other.

Can catch CTC clusters too.

Luckily, this makes the Parsortix machine ideal for so called "dual analysis".

This being CtDna analysis (analysing fragments of DNA found in blood) at the same time as CTC DNA analysis.

- Finds about twice as many cancer cell biomarkers as CtDna alone.

All IMHO.

This was due in April, then March, now we are more than half way through June. What a joke! They should sack whoever is supposed to be sorting this out IMHO.

RaiseworldC.

Thank the Lord dual analysis has been independently confirmed by a couple of study's now.

CtDna analysis is making CTC analysis less important.

CtDna can't replace CTC analysis as some information is simply not there.

But a lot of it is, and it's easier and cheaper.

However, as luck would have it, we now have dual analysis and without CTC's it can't be done.

Thus, Angle Plc need to fully focus on dual analysis.

The CtDna Co's MUST know this.

They can analyse CtDna to death but they will never find the information in CTC’s because it does not exist in CtDna.

All IMHO.

RaiseworldC

"It’s all good. Stay positive."

===================

In time you too will suspect Mr Newland has got his priorities wrong.

He does NOT seem to be focused on orders and invoices.

He revells in things parsortix has enabled. Great.

That does NOT pay the bills.

Also he claims to have been in so many discussions about contracts it is unbelievable.

I mean I really don't believe it!

Angle have a fantastic opportunity now with dual analysis.

I have serious doubts Mr Newland is the right person.

All IMHO.

RaiseworldC.

Https://angleplc.com/translational-research/glioblastoma/

========================

Very interesting but it does not pay the bills.

Angle can advertise this on their web site etc. and maybe some orders for their Parsortix machine will turn up.

However, Angle have about 6 months to get some serious revenue in (over and above selling the machine and the consumables that go with it).

Mr Newland needs to FULLY focus on getting orders in and getting invoices out. The man needs to get his act together.

Maybe Astrazeneca or another Plc will want other assays developed. Hope so. Also, maybe Astra will use one or both of the assays Angle developed for them in actual cancer drug trials. Ditto Eisai Inc.

Until then Mr Newland needs Angle to put every effort into the dual analysis.

I’m beginning to think he simply does not understand where Angle are.

All IMHO.

Also potential bidders.

Getting FDA clearance for the Genedrive® MT-RNR1 won't have gone unnoticed by potential bidders.

IMHO that would be a gold mine.

All IMHO.

Mr Newland would be well advised to concentrate lab time on Angle's "dual analysis" as this is clearly the most obvious way of generating orders that lead to invoices. Something Mr Newland appears not to be used to. Obviousy Illumina believe it is a solid commercial oppertunity. It's all very well Angle have without doubt helped cancer research and this is on-going. Unfortunately that does not necessarily pay the bills. Angle's sales force performance is not good to say the least and needs shaking up or even replacing in my view. My Newland should have sorted this out by now.

All IMHO.

Monday 30th June. 12 days time. Shareholders are not best happy.

Stille

"Might be worth noting….

@EmeraldCarrots does not usually screw up"

=================

Ahem! Correct with this share so far. Some others have gone pear shaped!

Pratt & Whitney engines, the model that had the wear issue before. However that obviously has been sorted. At the and of the day WIZZ only have Airbus planes and Boeing are potentially in even more trouble if the Indian air disaster was to do with the plane. That plane had GE engines, I checked. WIZZ have a lot going for them if you ask me. The Israel/Iran conflict also may be over quite soon looking at the news.

Once they get over £16 a share I may be looking to sell some.

All IMHO.

Strange.

Installing what with the cardiavascular:-

"Genedrive® CYP2C19-ID Kit to be used to support expansion of use to include Acute Coronary Syndrome"

and the phased MT-RNR1 ID Kit orders:-

"NIHR and OLS Funding Package of c.£500k to address NICE Real World Evidence Generation Requirements for the Genedrive® MT-RNR1 ID Kit across 14 hospitals across the UK (PALOH-UK). Progressing as planned, with nine Group 1 sites live, with a further five Group 2 sites phased to go-live from May 2025".

2nd day up.

Bless 'em !!!!!!!!